The prevalent role of Th7 signaling in MASLD progression has been confirmed in a model of HFD mice, where the administration of monoclonal antibody targeting IL-17 induced a marked decrease in hepatic lipid accumulation and attenuated liver fibrosis (Figure 2) [68]. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.